

In the landmark STEP 1 trial, 44.2% of patients taking semaglutide 2.4 mg reported nausea at some point during treatment. That number sounds high, and it is worth understanding what it actually means. The vast majority of those cases were mild to moderate, temporary, and resolved within the first few weeks as the body adjusted to the medication. Fewer than 7% of participants stopped treatment because of GLP-1 side effects.
If you're considering GLP-1 treatment for weight loss, or you've recently started and are feeling uneasy, you're not alone. Side effects are common, they are well-studied, and in most cases, they are manageable with the right approach. This article breaks down the seven most commonly reported side effects from clinical trials, explains what causes them, and gives you practical strategies to reduce discomfort. We also cover when to contact your doctor and how semaglutide side effects compare to those of tirzepatide.
Whether you're taking Ozempic, Wegovy, or Rybelsus, understanding what to expect can make the first few weeks much smoother.
Nausea is the single most reported side effect across GLP-1 medications. In the STEP 1 trial studying semaglutide (the active ingredient in Wegovy and Ozempic), 44.2% of patients experienced nausea. In SURMOUNT-1, which studied tirzepatide (Mounjaro/Zepbound), nausea rates ranged from 24% at the 5 mg dose to 33% at 15 mg.
The good news: nausea is almost always temporary. It tends to peak during the first four to six weeks or after a dose increase, then fades as your body adapts. Most patients find it manageable without stopping treatment.
GLP-1 medications work partly by slowing gastric emptying, meaning food stays in your stomach longer than usual. This delayed emptying can create a feeling of fullness that tips into nausea for some people. GLP-1 receptors in the brainstem also play a role, as the medication activates areas that regulate nausea signalling.
Small dietary shifts can make a real difference:
If dietary changes are not enough, talk to your doctor. They may extend your time at the current dose before increasing, or in some cases, prescribe anti-nausea medication for short-term relief.
Vomiting is reported less often than nausea but still affects a meaningful number of patients. In STEP 1, 24.8% of semaglutide patients reported vomiting. In SURMOUNT-1, the rate was lower for tirzepatide, ranging from 5.7% at 5 mg to 12.2% at 15 mg.
Like nausea, vomiting tends to occur early in treatment or after a dose increase, and it typically resolves within the first few weeks.
The same dietary strategies that help with nausea apply here. Additional tips include:
If vomiting is persistent, your doctor may recommend stepping back to a lower dose temporarily. This is a normal part of the titration process and doesn't mean the medication isn't working for you.
Contact your doctor immediately if:
These symptoms could indicate pancreatitis or another serious condition that requires urgent evaluation.
Diarrhoea was reported by 31.5% of patients in STEP 1 (semaglutide) and 21-23% in SURMOUNT-1 (tirzepatide, dose-dependent). It is one of the more persistent gastrointestinal effects, though it usually remains mild.
If diarrhoea persists beyond four to six weeks or becomes severe, your doctor may adjust your dosing schedule. Severe or prolonged diarrhoea can lead to dehydration, which is particularly relevant for patients with kidney concerns.
Constipation is reported by roughly 24.2% of semaglutide patients (STEP 1) and 17-19% of tirzepatide patients (SURMOUNT-1). Unlike nausea, which usually fades within weeks, constipation can persist longer and requires active management.
Slowed gastric emptying affects the entire digestive tract, not just the stomach. Food and waste move through the intestines more slowly, leading to harder stools and less frequent bowel movements. Reduced food and fluid intake (a natural result of appetite suppression) can also contribute.
Managing GLP-1 side effects is easier with doctor support. Trimly includes unlimited follow-ups to help you through the adjustment period.
Book ConsultationHeadaches and fatigue are commonly reported during the first weeks of GLP-1 treatment. In the STEP 1 trial, headache was reported by 14.4% of semaglutide patients (compared to 12.5% on placebo), and fatigue by approximately 11%. Both are linked to the body adjusting to reduced calorie intake and changes in blood sugar levels.
GLP-1 medications naturally reduce your appetite, which means you eat less. For some people, the drop in calorie intake can be significant, sometimes dipping below the recommended daily minimum. When your body doesn't get enough fuel, fatigue is a predictable result.
Dehydration is another common cause. If you feel less hungry, you may also forget to drink enough water throughout the day.
Fatigue and headaches typically improve within 8 to 12 weeks. If they persist beyond that, let your doctor know. They may want to check for nutritional deficiencies or other contributing factors.
If you are taking GLP-1 medication alongside diabetes medications like insulin or sulfonylureas, fatigue and dizziness could signal low blood sugar (hypoglycaemia). Symptoms include shakiness, sweating, confusion, and a rapid heartbeat. Keep glucose tablets or a small juice on hand, and speak to your doctor about adjusting your diabetes medication doses.
For patients using injectable forms of GLP-1 medication (Wegovy, Ozempic, Mounjaro), injection site reactions are a possibility. In STEP 1, approximately 3.2% of patients reported reactions at the injection site, including redness, itching, swelling, or mild pain.
Injection site reactions are usually mild and resolve within a day or two. If you notice a hard lump, increasing redness, or signs of infection (warmth, pus, spreading redness), contact your doctor.
If injections are a concern for you, oral GLP-1 options like Rybelsus are available and eliminate this side effect entirely.
Reduced appetite is the primary mechanism through which GLP-1 medications help with weight loss. It's not technically a "side effect" in the traditional sense, but it requires monitoring to make sure you're still eating enough to stay healthy.
In clinical trials, appetite reduction is consistent across all GLP-1 medications. The STEP 1 trial showed that semaglutide patients achieved 14.9% weight loss over 68 weeks, largely driven by reduced calorie intake. SURMOUNT-1 demonstrated even greater weight loss with tirzepatide: 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks.
While eating less is part of how the medication works, eating too little can cause problems:
Your doctor can help you set safe weight loss targets and monitor for nutritional gaps. This is one of the reasons why regular follow-up consultations are valuable during GLP-1 treatment.
If you're weighing your medication options, comparing side effect profiles can help you make an informed decision with your doctor.
| Side Effect | Semaglutide 2.4 mg (STEP 1) | Tirzepatide 5 mg (SURMOUNT-1) | Tirzepatide 15 mg (SURMOUNT-1) |
|---|---|---|---|
| Nausea | 44.2% | 24.0% | 33.3% |
| Vomiting | 24.8% | 5.7% | 12.2% |
| Diarrhoea | 31.5% | 21.2% | 23.0% |
| Constipation | 24.2% | 17.1% | 19.2% |
| Headache | 14.4% | -- | -- |
| Fatigue | ~11% | -- | -- |
| Injection site reactions | 3.2% | -- | -- |
Sources: Wilding et al., NEJM 2021 (STEP 1); Jastreboff et al., NEJM 2022 (SURMOUNT-1)
A few things stand out from this comparison. Tirzepatide generally has lower rates of nausea and vomiting than semaglutide, especially at the lower 5 mg dose. Both medications have similar rates of diarrhoea and constipation. And both follow the same pattern: side effects are most common early in treatment and during dose increases, then decrease over time.
Your doctor can help you weigh these differences alongside factors like weight loss goals, cost, and personal preferences. For a broader comparison of weight loss medications available in Singapore, see our guide to weight loss medication.
One of the most effective ways to minimise side effects is through gradual dose increases, known as titration. This is why both semaglutide and tirzepatide have structured titration schedules.
Semaglutide (Wegovy) titration schedule:
- Weeks 1-4: 0.25 mg
- Weeks 5-8: 0.5 mg
- Weeks 9-12: 1.0 mg
- Weeks 13-16: 1.7 mg
- Week 17 onwards: 2.4 mg (maintenance dose)
Tirzepatide (Mounjaro) titration schedule:
- Weeks 1-4: 2.5 mg
- Dose increases by 2.5 mg every four weeks
- Available doses: 2.5, 5, 7.5, 10, 12.5, 15 mg
Each step gives your body time to adjust before the dose goes up. If side effects are particularly bothersome at any stage, your doctor may keep you at the current dose for an extra two to four weeks before moving to the next level. There is no need to rush titration.
This is where having a doctor who is accessible makes a real difference. At Trimly, you can message your doctor directly via WhatsApp if you experience side effects between consultations. That kind of responsive support helps you and your doctor find the right pace for dose increases, reducing unnecessary discomfort.
While the side effects discussed above are common and manageable, there are rare but serious complications that require immediate medical attention. These affect a very small percentage of patients, but it is important to recognise the warning signs.
Severe, persistent pain in the upper abdomen that radiates to your back, especially when accompanied by nausea, vomiting, or fever, could indicate pancreatitis. The incidence in clinical trials is less than 1%, but if you experience these symptoms, stop your medication and seek medical attention immediately.
GLP-1 medications have been associated with a higher risk of gallbladder problems, including gallstones. Watch for pain in the upper right side of your abdomen, bloating, fever, chills, or yellowing of the skin or eyes. Rapid weight loss itself also increases gallbladder risk, which is another reason why gradual, medically supervised weight loss is safer.
Signs of a serious allergic reaction include difficulty breathing, swelling of the face, lips, tongue, or throat, severe rash or hives, and rapid heartbeat. These are rare but require emergency care.
GLP-1 medications carry a boxed warning about medullary thyroid carcinoma (MTC) based on animal studies. This is why they are contraindicated for anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2. If you notice a lump or swelling in your neck, persistent hoarseness, or difficulty swallowing, tell your doctor.
If you experience any of these serious symptoms, go to your nearest A&E. For less urgent concerns, telehealth monitoring allows your doctor to assess symptoms quickly and determine the best course of action.
Managing GLP-1 weight loss side effects is much smoother when you have easy access to your doctor. That is where telehealth changes things. Instead of waiting weeks for a clinic appointment to address a side effect, you can connect with your doctor from home.
At Trimly, every patient gets:
This level of support matters most during the first few months of treatment, when side effects are most likely. If nausea hits after a dose increase, you don't need to "tough it out" or wait for your next scheduled visit. You can reach out, get guidance, and have your plan adjusted the same day.
Trimly's doctors are experienced with GLP-1 prescribing and understand the typical adjustment period. They can help you distinguish between side effects that will pass on their own and symptoms that need a change in approach. All of this happens under proper medical supervision, in line with Singapore's telehealth regulations.
Want doctor support to manage your GLP-1 side effects? Trimly includes unlimited follow-ups and WhatsApp doctor access from $350/month.
Book ConsultationMost GLP-1 side effects are temporary. Nausea and vomiting typically peak in the first four to six weeks and improve as your body adjusts. Constipation may take longer to resolve and sometimes requires ongoing management. The majority of patients find that side effects become significantly milder by week 8 to 12.
Ozempic (semaglutide, approved for diabetes) and Wegovy (semaglutide, approved for weight management) contain the same active ingredient. Wegovy uses a higher maintenance dose (2.4 mg vs 1.0 mg for Ozempic), so side effects may be more pronounced at the higher dose. The types of side effects are the same.
Yes. You should never feel forced to continue a medication that is causing you significant discomfort. Talk to your doctor before stopping, as they may be able to reduce your dose or try a different approach first. Stopping abruptly is safe but may cause a return of appetite and weight regain. Your doctor can help you plan the best way forward.
Not necessarily. Side effects are a sign that your body is adjusting to the medication, but their presence or absence doesn't predict how well the medication will work for weight loss. Some patients experience strong side effects with excellent results. Others have minimal side effects and still lose weight effectively.
Stick to light, bland foods: plain rice, steamed chicken, crackers, bananas, and clear soups. Avoid greasy, fried, or heavily spiced foods. Eat small portions and stop when you feel full. Stay hydrated with water or ginger tea.
GLP-1 side effects are well-documented, predictable, and in most cases, temporary. Here is a summary of what to keep in mind:
Starting GLP-1 treatment is a significant step, and it's normal to feel cautious about side effects. The clinical evidence shows that with proper medical supervision, slow titration, and simple lifestyle adjustments, most patients tolerate these medications well. The temporary discomfort of side effects is often outweighed by the sustained weight loss and health improvements that follow.
If you're considering GLP-1 treatment or already managing side effects, having a doctor who's responsive and accessible can make all the difference. Trimly's doctors check multiple factors before prescribing and stay with you throughout treatment to ensure your experience is as smooth as possible.